NovoCure Ltd — Director's Dealing 2021

Sep 3, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2021-09-01

Reporting Person: Burke William Patrick (Chief Human Resources Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	10283	Direct
Restricted Share Units	2657	Direct
Restricted Share Units	4804	Direct
Restricted Share Units	1573	Direct
Restricted Share Units	3266	Direct
Restricted Share Units	3634	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to Buy Ordinary Shares	$11.46	2026-02-24	Ordinary Shares (17452.0)		Direct
Options to Buy Ordinary Shares	$7.15	2027-02-21	Ordinary Shares (9750.0)		Direct
Options to Buy Ordinary Shares	$21.6	2027-10-30	Ordinary Shares (7500.0)		Direct
Options to Buy Ordinary Shares	$21.15	2028-02-26	Ordinary Shares (32103.0)		Direct
Options to Buy Ordinary Shares	$47.04	2029-03-21	Ordinary Shares (10946.0)		Direct
Options to Buy Ordinary Shares	$69.37	2030-03-02	Ordinary Shares (13896.0)		Direct
Options to Buy Ordinary Shares	$84.68	2030-08-31	Ordinary Shares (4535.0)		Direct
Options to Buy Ordinary Shares	$153.09	2031-03-01	Ordinary Shares (6001.0)		Direct
Options to Buy Ordinary Shares	$137.58	2031-08-31	Ordinary Shares (6531.0)		Direct

Footnotes

F1: Represents restricted share units that are scheduled to vest on March 22, 2022, subject to the reporting person's continued employment through such date.

F2: Represents restricted share units that are scheduled to vest on March 3, 2022 and 2023, subject to the reporting person's continued employment through such dates.

F3: Represents restricted share units that are scheduled to vest on September 1, 2022 and 2023, subject to the reporting person's continued employment through such dates.

F4: Represents restricted share units that are scheduled to vest on March 2, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.

F5: Represents restricted share units that are scheduled to vest on September 1, 2022, 2023 and 2024, subject to the reporting person's continued employment through such dates.

F6: Fully vested as of the date hereof.

F7: These options vest on October 31, 2021, subject to the reporting person's continued employment through such date.

F8: Options to buy 32,103 ordinary shares, 24,078 shares of which are currently exercisable and the remaining 8,025 vest and become exercisable on February 27, 2022, subject to the reporting person's continued employment through such date.

F9: Options to buy 10,946 ordinary shares, 3,649 shares of which are currently exercisable and the remaining 7,297 shares of which will vest and become exercisable in equal installments on each of March 22, 2022 March 22, 2023, subject to the reporting person's continued employment through such dates.

F10: Options to buy 13,896 ordinary shares, 3,474 shares of which are currently exercisable and the remaining 10,422 shares will vest and become exercisable in equal installments on each of March 3, 2022, March 3, 2023 and March 3, 2024, subject to the reporting person's continued employment through such dates.

F11: Options to buy 4,535 ordinary shares, 1,134 shares of which are currently exercisable and the remaining 3,401 shares will vest and become exercisable in equal installments on each of September 1, 2022, September 1, 2023 and September 1, 2024, subject to the reporting person's continued employment through such dates.

F12: One-quarter of these options is scheduled to vest on each of March 2, 2022, March 2, 2023, March 2, 2024 and March 2, 2025, subject to the reporting person's continued employment through such dates.

F13: One-quarter of these options is scheduled to vest on each of September 1, 2022, September 1, 2023, September 1, 2024 and September 1, 2025, subject to the reporting person's continued employment through such dates.